In summary, Cystatin C represents a very sensitive and specific biomarker to predict AKI in patients under-going thoracic surgery with MHCA even before surgery, whereas the predictive capacity of [TIMP-2]*[IGFBP7] is only moderate. This evidence concerns the gene IGFBP7 and acute kidney injury.